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Abstract
Objective
Remission is a key goal in managing rheumatoid arthritis (RA), with sustained remission as
the preferred sequelae of short-term remission. However little is known about the predictors
of sustained remission for patients reaching remission. Using two independent cohorts, we
aimed to evaluate the prevalence and predictors for sustained remission.
Methods
The study cohort consisted of subjects with RA from the Brigham and Women’s Hospital
Rheumatoid Arthritis Sequential Study (BRASS) and the Korean Observational Study Net-
work for Arthritis (KORONA). We analyzed subjects who reached remission in 2009 with fol-
low up data for two consecutive years. Remission was defined by the Disease Activity Score
28- (DAS28-CRP) of less than 2.6. Sustained remission was defined as three consecutive
annual visits in remission. Predictors for sustained remission were identified by multivariate
logistic regression analysis.
Results
A total of 465 subjects were in remission in 2009. Sustained remission was achieved by 53
of 92 (57.5%) in BRASS and by 198 of 373 (53.1%) in KORONA. In multivariate analyses,
baseline predictors of sustained remission were: disease duration less than 5 years [odds
ratio (OR) 1.96, 95% confidence interval (95% CI) 1.08–3.58], Modified Health Assessment
Questionnaire (MHAQ) score of 0 (OR 1.80, 95% CI 1.18–2.74), and non-use of oral gluco-
corticoid (OR 1.58, 95% CI 1.01–2.47).
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Conclusion
More than half of RA subjects in remission in 2009 remained in remission through 2011.
Short disease duration, no disability, and non-use of oral glucocorticoid at baseline were
associated with sustained remission.
Introduction
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease that affects synovial
joints. The pathology of the disease process often leads to serious functional disability and
chronic pain caused by destruction of the joint [1]. Previous studies have reported that inten-
sive management of RA improves radiographic disease progression, physical function, and
quality of life [2–5]. Hence, remission is a key goal that is now achievable with advances in
available therapies [6, 7]. Since disease progression is more likely to occur in patients achieving
short-term remission than in those achieving sustained remission, which is more likely to
improve patient outcomes [7]. However, a small number of patients can achieve sustained
remission in clinical practice [8], and disease flare and recurrence can happen unexpectedly,
even if patients achieve remission [3]. Therefore, identifying the predictors of sustained remis-
sion in clinical practice is important for physicians and patients to plan treatments.
Until now, several studies identifying predictors for sustained remission have been con-
ducted, and they suggest that male sex, younger age, short duration of symptoms, few tender
joints count, low functional disability, low disease activity or radiologic score, and a good
response to initial treatment at baseline are independent predictors [9–13]. However, various
definitions of remission in RA have been used and the rates of remission have been reported
differently according to criteria [14–16]. In addition, definitions of sustained remission varied
across studies, and there are only a few studies that have assessed a remission longer than one
year. Most prior studies focused on early RA, even though most RA patients in clinical practice
have suffered from the disease for a long time.
In this study, we aimed to investigate the prevalence of sustained remission in established
RA patients, and to identify the predictors for this.
Patients and methods
Study design and data sources
We combined data from two large RA cohorts. The Brigham and Women’s Hospital Rheuma-
toid Arthritis Sequential Study (BRASS) is a single-center, prospective, observational cohort of
over 1,300 RA patients [17]. Enrollment for the registry began in March of 2003 in the Brig-
ham and Women’s Hospital Arthritis Center in the United States. At the baseline visit and at
each annual follow up visit, patient’s rheumatologists complete forms detailing extra-articular
manifestations, comorbidities, medication changes, laboratory test results, 28-joint count and
overall disease activity score. A trained staff member interviews the patient and the patient fills
out a self-administered questionnaire containing questions about medication and patient-
reported outcomes. Patient questionnaires are completed every six months.
The KORean Observational study Network for Arthritis (KORONA) is a multicenter, pro-
spective, observational cohort of Korean RA patients. It was established in 2009 by the Clinical
Research Center for Rheumatoid Arthritis in Hanyang University funded by the ministry of
health and welfare, South Korea [18]. All RA patients aged 18 or older who satisfied the 1987
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American College of Rheumatology criteria for RA and who planned to have their blood
drawn for routine evaluation were asked to provide informed consent. Of these, more than
95% of patients consented to participate in the KORONA cohort [18]. All enrolled patients
completed an initial questionnaire to establish their demographic profile, medical history, and
disease-specific outcomes. Disease activity with joint assessments were made by patient’s rheu-
matologists or well-trained medical staffs. These evaluations, together with laboratory test
results, prescription information, and patient self-evaluations are integrated in the database
and they are completed with annual follow-up. A total of 5,300 RA patients from 23 South
Korean centers have been included in KORONA.
Study participants
Both cohorts have a similar study design and subject inclusion criteria: patients with estab-
lished RA diagnosed by rheumatologists, with virtually all patients aged over 18 years at their
enrollment. However, since differences in initial enrollment periods for each cohort can influ-
ence drug availability, we restricted this study to include subjects who had an annual visit from
2009 through 2011 (n = 382 in BRASS and n = 1,290 in KORONA). Among them, a total of
1171 patients (188 in BRASS and 983 in KORONA) who had 3 years of disease activity data
were selected for complete case analysis. For the analysis of prevalence and predictors for sus-
tained remission lasting two consecutive years, we further selected patients who were in remis-
sion in 2009 (S1 Fig). Each patient signs an informed consent form that was obtained
according to the Declaration of Helsinki and approved by the Partners Institutional Review
Board (IRB) at Brigham and Women’s Hospital and IRB at Hanyang University Hospital
(HYUH 2009-04-003). The current analytic protocol was approved by the Partners Institu-
tional Review Board (IRB) at Brigham and Women’s Hospital (# 2012P-00096).
Sustained remission
Disease activity status was determined using disease activity score (DAS) 28 based on C reac-
tive protein (CRP) scores [19]. DAS28-CRP was calculated using four variables [DAS28-CRP
(4)]: swollen and tender joint counts, CRP, and patient global assessment. Remission was
defined by DAS28-CRP(4) remission (score< 2.6) primarily; we also assessed rates of remis-
sion by the American College of Rheumatology (ACR)/European League Against Rheumatism
(EULAR) remission criteria. We included in this study patients achieving DAS28-CRP(4)
remission in 2009. Patients were classified as being in “sustained remission” if they were in
DAS28-CRP(4) remission at 2 consecutive annual visits after baseline. We conducted a nested
case-control study of patients with or without sustained remission.
Statistical analysis
We used descriptive statistics to characterize baseline patient demographics and disease char-
acteristics in each cohort separately and in aggregate. The duration of remission was character-
ized for all subjects in remission in 2009, examining the annual assessments in 2010 and 2011.
The rates of sustained remission were compared across cohorts and bivariable relationships
between sustained remission and demographic features such as age, sex, body mass index
(BMI), income, and education level as well as clinical features such as disease duration, pres-
ence of disability, medication such as disease modifying antirheumatic drugs (DMARDs),
non-steroidal anti-inflammatory drugs (NSAIDs), pain killer, glucocorticoid, anti-osteopo-
rotic medication and autoantibody positivity were examined.
Variables significant at the P<0.25 level in the univariate model were advanced to multivar-
iate logistic regression models to determine predictors of sustained remission. Predictors and
Sustained remission in rheumatoid arthritis
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parameter estimates of each cohort were very similar. Thus, we fit a model combining cohorts
with an indicator term for cohort (BRASS or KORONA)
All statistical analyses were conducted using SAS System for Windows version 9.2 (SAS
Institute Inc., Cary, N.C.) and SPSS version 18.0 (SPSS Inc, Chicago IL). Results were consid-
ered statistically significant when P values were less than 0.05.
Results
Demographic and clinical characteristics
Among the subjects who had 3 years follow up data of disease activity (n = 1,171), the point
prevalence of DAS28-CRP(4) remission in 2009 was 39.7% in total (49.2% in BRASS and
37.9% in KORONA), whereas ACR/EULAR remission in 2009 was only 8.5% (6.4% in BRASS
and 8.7% in KORONA) (S1 Fig). A total of 465 RA subjects from BRASS (n = 92) and KOR-
ONA (n = 373) with remission according to DAS28-CRP(4) were selected for our study. The
demographic and clinical characteristics at baseline are summarized by each cohort in Table 1.
The proportion of females among total subjects was 81.9% and the mean age was 55.5±11.7
years. Although there was no difference in age (P = 0.78) and sex (P = 0.91) between two
cohorts, BRASS subjects had longer disease duration, higher income and education level, and
higher BMI compared to KORONA. Subcutaneous nodules were more common among
BRASS subjects, whereas rheumatoid factor (RF) and anti-citrullinated protein antibody
(ACPA) were more common among KORONA subjects (91.7% and 89.0% in KORONA sub-
jects compared to 62.7% and 60.9% in BRASS subjects, P < 0.01). Composite measures of dis-
ease activity were slightly worse among BRASS subjects than KORONA, but functional
disability measured with modified health assessment questionnaire score (MHAQ) and the
number of co-morbidity were similar between two cohorts.
Patterns of medication use for subjects in remission were quite different between the two
cohorts. Biologic disease modifying anti-rheumatic drugs (DMARDs) were more commonly
used in BRASS, whereas methotrexate and glucocorticoid were commonly used in KORONA.
Prevalence of sustained remission
Two hundred and fifty-one (21.6%) subjects who had 3 years follow up data (n = 1,171)
achieved sustained remission from 2009 to 2011. The prevalence of DAS28-CRP(4) sustained
remission for subjects with remission in 2009 (n = 465) was 54.0%. The prevalence of
DAS28-CRP(4)sustained remission was similar for BRASS (57.5%) and KORONA (53.1%)
(P = 0.44, Table 2A). The prevalence of ACR/EULAR sustained remission for subjects with
remission in 2009 (n = 99) was only 17 (17.2%) with no significant difference between BRASS
and KORONA (P = 0.13, Table 2B)
Predictors for sustained remission
In the unadjusted logistic regression model with DAS28-CRP(4) sustained remission as the
outcome (Table 3), variables associated with sustained remission included: younger age (odds
ratio [OR] 2.53, 95% confidence interval [95% CI] 1.42–4.53 for less than 45 years and OR
1.70, 95% CI 1.08–2.67 for 45–64 years group), shorter disease duration (OR 1.92, 95% CI
1.14–3.24 for less than 5 years and OR 1.72, 95% CI 1.00–2.95 for 5–9 years group), and higher
education level (OR 1.70, 95% CI 1.15–2.50). In addition, MHAQ of 0 (OR 2.27, 95% CI 1.54–
3.36) non-use of oral glucocorticoid (OR 1.49, 95% CI 1.03–2.17) at baseline were associated
with sustained remission.
Sustained remission in rheumatoid arthritis
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Table 1. Baseline characteristics of the study population (in 2009).
Individual characteristics Total
(n = 465)
BRASS
(n = 92)
KORONA
(n = 373)
P
emographic feature
Age in years, mean (SD)� 55.5 (11.7) 55.2 (11.1) 55.6 (11.9) 0.624
Female 381 (81.9) 75 (81.5) 306 (82.0) 0.507
Education level <0.001
~ High school 300 (64.8) 52 (28.0) 277 (74.3)
College ~ 163 (35.2) 134 (72.0) 96 (25.7)
NA 2 2 0
Income ($/year) <0.001
~9,999 121 (26.3) 1 (1.1) 120 (32.3)
10,00 216 (47.0) 11 (12.4) 205 (55.3)
50,000~89,999 56 (12.2) 17 (19.1) 39 (10.5)
90,000~ 67 (14.6) 60 (67.4) 7 (1.9)
NA 5 3 2
Body mass index, mean (SD)� kg/m2 23.1 (3.9) 25.9 (5.3) 22.4(3.1) <0.001
Clinical features
Years with RA, mean (SD)� 9.2 (8.1) 14.3 (9.0) 7.9 (7.3) 0.001
Tender joint count, mean (SD)� 0.3 (0.7) 0.3(0.7) 0.4 (0.7) 0.870
Swollen joint count, mean (SD)� 1.1 (1.3) 1.0 (1.9) 0.3(0.8) <0.001
Rheumatoid nodule 27 (5.8) 12 (13.3) 15 (4.0) <0.001
Modified HAQ, mean (SD)� 0.14 (0.30) 0.14 (0.30) 0.14 (0.31) 0,796
DAS28-CRP(4), mean (SD)� 1.9 (0.4) 1.7 (0.4) 2.0 (0.4) 0.016
SDAI, mean (SD)� 5.1 (2.5) 3.9 (3.1) 5.4 (2.8) 0.359
CDAI, mean (SD)� 4.8 (2.9) 3.8 (3.1) 5.0 (2.8) 0.338
Rheumatoid factor positivity 394/456 (86.4) 52/83(62.7) 342 (91.7) <0.001
ACPA positivity 322/391(82.4) 56 (60.9) 266/299 (89.0) <0.001
Charlson Comorbidity Index, mean (SD)� 0.37 (0.65) 0.3(0.6) 0.4 (0.7) 0.138
ACR/EULAR remission 98 (21.1) 12 (13.0) 86 (23.1) 0.021
Treatment
Biologics DMARD 73 (15.7) 52 (56.5) 21 (5.6) <0.001
Non-biologic DMARD 438 (94.2) 68 (73.9) 967 (98.4) <0.001
Methotrexate 393 (84.5) 58 (63.0) 335 (89.8) <0.001
Methotrexate dose, mean (SD)� mg/week 13.3 (4.0) 17.2 (6.1) 12.6 (3.0) <0.001
Leflunomide 166 (35.8) 4 (4.3) 162 (43.5) <0.001
Non-steroidal anti-inflammatory drug. 193 (41.5) 44 (47.8) 149 (39.9) 0.105
Cyclooxygenase-2 inhibitor 98 (21.1) 8 (8.7) 90 (24.1) <0.001
Acetaminophen 37 (8.0) 20 (21.7) 17 (4.6) <0.001
Opioid 14 (3.0) 3(3.3) 11(2.9) 0.508
Anti-osteoporotic medication 149 (32.0) 59 (64.1) 90 (24.1) <0.001
Glucocorticoid 286 (61.6) 17 (18.7) 269 (72.1) <0.001
Glucocorticoid dose, mean (SD)� mg/day 4.0 (1.9) 2.3 (1.4) 4.2 (1.8) 0.250
� Except where indicated otherwise, values are the number (%). BRASS, Brigham Rheumatoid Arthritis Sequential Study; KORONA, KORean Observational study
Network for Arthritis; RA, rheumatoid arthritis; SD, standard deviation; NA, not available; ACPA, anti-citrullinated protein antibody; HAQ, health assessment
questionnaire; DAS28-CRP(4), disease activity score 28-C-reactive protein using 4 variables; CDAI, clinical Disease Activity; SDAI, Simplified Disease Activity Index;
ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; DMARD, disease modifying anti-rheumatic drug.
https://doi.org/10.1371/journal.pone.0214981.t001
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In a multivariate model predicting sustained remission, we included all of the above signifi-
cant variables and those with p< 0.25 in unadjusted regression. As shown in Table 3, disease
duration less than 5 years (OR 1.96, 95% CI 1.08–3.58), MHAQ of 0 (OR 1.80, 95% CI 1.18–
2.74), and non-use of glucocorticoid (OR 1.58, 95% CI 1.01–2.47) were significantly associated
with increased odds for sustained remission in RA. Cohort (BRASS or KORONA) was not a
predictor for sustained remission in multivariate model. The multivariate models for each
cohort were presented in S1 Table.
Discussion
The present study investigated the prevalence and predictors for sustained remission in estab-
lished RA. The long-term follow-up data from the BRASS and KORONA cohorts revealed that
sustained remission occurred during 2009 through 2011 in 54.0% of patients with remission in
2009. Disease duration less than 5 years, MHAQ of 0, and non-use of oral glucocorticoid were
predictors of sustained remission in multivariate analysis.
Most studies about predictors for sustained remission have been reported in early RA
cohorts [9, 11, 12, 20], but few studies have been performed in established RA. In early RA
cohorts, low disease activity at baseline [9, 12, 20], short symptom duration [11, 12], male [12,
20], younger age [20], the absence of autoantibodies [11], and lesser radiologic score at base-
line [9] were all predictors for sustained remission. However, our study using established RA
cohort did not find the association of sex, age, and the negativity of RF with sustained remis-
sion. Until now, only two studies of established RA exist from the Consortium of Rheumatol-
ogy Researchers of North America (CORRONA) database [21, 22]. One study examined early
and established disease cohorts separately and found that male sex is the major predictor for
sustained remission in early diseases but not in established RA. Conversely, the use of gluco-
corticoid and disease activity at baseline were inversely associated with sustained remission in
established RA patients [22]. Our results were similar to the results of the previous CORRONA
study in which they show that the baseline characteristics that are indicative of less severe or
well controlled disease might be associated with sustained remission and sex was not a predic-
tor for sustained remission in established RA patients. While the present study is similar to
Table 2. Prevalence of sustained remission among patients with remission in 2009.
A. Sustained remission according to DAS 28-CRP(4)
Remission 2009 2010 2011 Total (n, %) BRASS (n, %) KORONA (n, %) P
Sustained
��
R R R 251 (54.0) 53 (57.5) 198 (53.1) 0.44
�
Not sustained R R A 86 (18.5) 17 (18.5) 69 (18.5)
R A R 68 (14.6) 11 (12.0) 57 (15.3)
R A A 60 (12.9) 11 (12.0) 49 (13.1)
Patients with remission in 2009 465 (100) 92 (100) 373 (100)
B. Sustained remission according to ACR /EULAR remission criteria
Sustained
��
R R R 17 (17.2) 4 (33.3) 13 (14.9) 0.13
�
Not sustained R R A 13 (13.1) 3 (25.0) 10 (11.5)
R A R 18 (18.2) 1 (8.3) 17 (19.5)
R A A 51 (51.5) 4 (33.3) 47 (54.0)
Patients with remission in 2009 99 (100) 12 (100) 87 (100)
�
sustained remission or not in patients with remission in 2009
��
sustained remission from 2009 to 2011; BRASS, Brigham Rheumatoid Arthritis Sequential Study; KORONA, KORean Observational study Network for Arthritis;
ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; R. remission; A, active.
https://doi.org/10.1371/journal.pone.0214981.t002
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Table 3. Predictors for sustained remission in rheumatoid arthritis patients (n = 465).
Variables Univariate analysis Multivariate analysis
P OR CI
Cohort
BRASS (n = 92) 1.20 (0.76–1.90) 0.85 1.06 (0.58–1.95)
Age (years)
65 ~ (n = 88) 1 0.31 1
45 ~ 64 (n = 270) 1.70 (1.08–2.67)� 0.25 1.33 (0.82–2.17)
~ 44 (n = 107) 2.53 (1.42–4.53)� 0.13 1.66 (0.86–3.21)
Years with RA
15 ~ (n = 165/463) 1 0.16 1
10 ~ 14.9 (n = 137/463) 1.77 (0.94–3.31) 0.08 1.82 (0.93–3.55)
5 ~ 9.9 (n = 73/463) 1.72 (1.00–2.95)� 0.09 1.68 (0.93–3.04)
~ 4.9 (n = 88/463) 1.92 (1.14–3.24)� 0.03 1.96 (1.08–3.58)��
Education level
~ High school diploma (n = 300/463) 1 1
College ~ (n = 163/463) 1.70 (1.15–2.50)� 0.22 1.34 (0.84–2.15)
Sex
Male (n = 84) 1.40 (0.86–2.26) 0.30 1.21 (0.78–1.86)
Modified HAQ
Score = 0 (no disability) (n = 299/459) 2.27 (1.54–3.36) � 0.01 1.80 (1.18–2.74) ��
Glucocorticoid use
No (n = 278) 1.49 (1.03–2.17) � 0.05 1.58 (1.01–2.47) ��
Charson comorbidity index
No (n = 329) 1.42 (0.95–2.12) 0.39 1.21 (0.78–1.87)
Rheumatoid factor
Negative (n = 394/456) 1.40 (0.81–2.42) 0.44 1.27 (0.69–2.35)
Anti-citrullinated protein antibody
Negative (n = 69/391) 1.04 (0.62–1.75)
Income ($/year)
~9,999 (n = 121/460) 1
10,000~49,999 (n = 216/460) 1.35 (0.86–2.76)
50,000~89,999 (n = 56/460) 1.87 (0.98–3.58)
90,000~ (n = 67/460) 1.47 (0.81–2.68)
Obesity (Body mass index)
Underweight ~18.4 (n = 29/462) 0.68 (0.31–1.47)
Normal 18.5~24.9 (~22.9 in WPRO) (n = 248/462) 1
Pre-obese 25~29.9 (23~24.9 in WPRO) (n = 94/462) 1.18 (0.73–1.89)
Obese 30~ (25~ in WPRO) (n = 91/462) 0.93 (0.58–1.50)
Biologic DMARD
Yes (n = 73) 0.91 (0.55–1.51)
Non-biologic DMARD
Yes (n = 438) 0.80 (0.36–1.75)
Methotrexate use
Yes (n = 393) 0.76 (0.46–1.26)
Non-steroidal anti-inflammatory drug use
(Continued)
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this prior work, it is difficult to compare the results of two studies because our study was differ-
ent in several regards. First, the definition of sustained remission in the prior work was the
remission of 2 consecutive visits after baseline that were more than 2 months, and up to 6
months, apart. Our definition of sustained remission required 3 visits over 2 years in remis-
sion. Second, disease activity measure was clinical disease activity index (CDAI) in the previ-
ous study and DAS28-CRP(4) for our study. Third, variables used in the predictive models
varied.
As other studies have demonstrated, patients with shorter RA duration are more likely to
achieve remission [23]. In our study, shorter RA duration and MHAQ of 0 were identified as
predictors of sustained remission in established RA patients. This finding supports the concept
of a therapeutic window of opportunity early in the disease course and indicates that early
intervention that induce remission before development of functional disability may be critical
for sustained remission. Non-use of oral glucocorticoid was also associated with sustained
remission. However, further study should be performed to identify whether it is from the glu-
cocorticoid use or other confounders, such as biologic agents or the severity of the underlying
disease
Our study has several important strengths. First, our definition of sustained remission was
over 2 years in remission and it is longer than previous studies. Second, our study was per-
formed with established RA patients. Although it is difficult to achieve remission in these
patients, we can try to taper DMARDs. Therefore, this information regarding sustained remis-
sion in established RA patients can be used as the basis for tapering DMARDs therapy.
We acknowledge the limitations of our work. First, we restricted the population to the same
period from the two cohorts which were established in different time periods. This may cause
selection bias in the BRASS cohort because it was established before KORONA, although it
allows us to compare the two cohorts with similar drug availability. According to a previous
report, patients with a shorter disease duration, higher disease activity, and several other socio-
economic factors were associated with the loss to follow-up from the BRASS cohort [24]. In
addition, we used listwise deletion as a method for handling missing data, because these data
go missing completely at random. Although this may cause selection bias, we did not perform
data imputation because our outcome for regression analysis was remission based on disease
activity. Furthermore, because both cohorts enrolled patients with RA regardless of their dis-
ease duration, we could not confirm at enrollment whether or not the patients were in remis-
sion for the first time. Second, the patients were assessed for remission according to
DAS28-CRP(4) criteria (<2.6). Although a previous study reported the tendency for
DAS28-CRP(4) to underestimate DAS28-ESR(4) and recommended that the thresholds for
remission should be changed to 2.3 in using DAS28-CRP(4), this only has a marginal improve-
ment over the original cut-off of 2.6 for DAS28-CRP(4) in another study [25]. For the strict
criteria for remission, although there is the ACR/EULAR remission criteria, we decided to use
the DAS28-CRP(4) remission criteria because this is more commonly used in clinical practice
Table 3. (Continued)
Variables Univariate analysis Multivariate analysis
P OR CI
Yes (n = 193) 1.07 (0.74–1.55)
�
P<0.05 in univariate analysis
��
P<0.05 in multivariate analysis; OR, odds ratio; CI, 95% confidence interval; BRASS, Brigham Rheumatoid Arthritis Sequential Study; HAQ, health assessment
questionnaire; WPRO, world health organization western pacific region office; DMARD, disease-modifying anti-rheumatic drug
https://doi.org/10.1371/journal.pone.0214981.t003
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and its psychometric properties are excellent [26]. However, since it is more liberal in defining
remission, it allowed us to identify additional predictors for sustained remission. Third, we
have assumed that the levels of disease activity evaluated at the 1 year time point represents a
stable period in a particular disease activity state, whereas in reality, patients may have experi-
enced limited fiares during that time. Although this ‘area under the curve’ approach to evaluate
longitudinal disease activity would be ideal, it is difficult in the setting of standard clinical care.
Hence we regarded sustained remission as staying in a remission state for 3 consecutive annual
visits during a 2 year time period to ensure that the disease activity period was stable. Fourth,
we assembled two cohorts from different countries, and while the baseline characteristics dif-
fered, the predictors of sustained remission were similar and the cohort was not a significant
in adjusted models. An interesting observation from our results is that the proportion of sus-
tained remission in patients with remission in 2009 in each cohort was not different. However,
we could not assess the drug adherence (which can affect the remission rate in each cohort)
although we did assess the several treatments such as DMARDs, pain killers and glucocorti-
coids. Lastly, the point prevalence of remission in 2009 is quite similar to that obtained for the
groups in the BeSt study (38–46%), but higher than our previous study [18] and other observa-
tional studies [21, 27]. However, this might be from the inclusion period used in our study.
Since we used recent data between 2009 and 2011, the remission rate would be higher than
before due to the availability of new treatment options and guidelines.
Conclusions
Our study demonstrated that the 2 year sustained remission rate of subjects in remission in
2009 was 54%. We identified several predictors of sustained remission that might be useful in
stratifying patients with established RA in typical practice. Such variables may help identify
patients who can attempt discontinuation of DMARDs or whose therapy should be closely
monitored since they are a great risk of flares after reaching remission.
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